ViroGates A/S (CPH: VIRO)

Market Cap	34.80M
Revenue (ttm)	6.90M
Net Income (ttm)	-13.13M
Shares Out	6.44M
EPS (ttm)	-2.04
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,133
Open	5.90
Previous Close	5.40
Day's Range	5.45 - 5.90
52-Week Range	4.98 - 19.51
Beta	0.94
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 7, 2024

About ViroGates

ViroGates A/S, an in vitro diagnostics company, develops and markets prognostic products for the healthcare sector. It offers suPARnostic, a proprietary biomarker used in hospital emergency services to support the clinical decision on hospitalization or discharge of acute patients and to identify high-risk sepsis patients at an early stage, as well as used for the prognosis of lifestyle-related diseases, such as cardiovascular disease, type 2 diabetes, and cancer; and for the assessment of longevity and biological age in a non-hospital setting....

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2000
• Employees: 10
• Stock Exchange: Copenhagen Stock Exchange
• Ticker Symbol: VIRO

Financial Performance

In 2023, ViroGates's revenue was 6.99 million, a decrease of -54.02% compared to the previous year's 15.20 million. Losses were -12.10 million, 25.4% more than in 2022.